XBiotech Inc. (XBIT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Austin, TX, 미국. 현재 CEO는 Sushma Shivaswamy.
XBIT 을(를) 보유 IPO 날짜 2015-04-15, 92 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $75M.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
